UPST

Upstart's FY2025 is a genuine inflection: revenue rose 64% to $1.04B and the company swung to a $53.6M net profit ($0.45 diluted EPS) after three straight loss years, so the turnaround is real, not cosmetic. But the quality of that profit is thin and fragile. Operating margin is just 4.1% and net margin 5.1%, ROE is 6.7%, and — most tellingly — operating cash flow was NEGATIVE $148M (down 179% YoY) even as GAAP net income turned positive. That divergence, driven largely by loans Upstart holds on its own balance sheet (the 10-K notes 10% of marketplace volume and a portfolio of 'R&D Loans'), means reported earnings are not converting to cash; group cash fell 17% to $652M and retained earnings remain a -$358M deficit.

The business is structurally cyclical and capital-markets-dependent in ways the numbers make vivid. Revenue has whipsawed — $849M (2021) → $842M → $514M (2023) → $637M → $1.04B — so this is a high-beta originator whose top line can halve in a downturn, not a steady compounder. The 10-K's own risk summary leads with economic sensitivity and funding fragility: it depends on retaining a limited number of lending partners and on institutional investors who buy 64% of volume, warns it 'may not be able to sustain or achieve profitability,' and flags single-product concentration. The MD&A's credit disclosure is a yellow flag: Q4-2023 and Q1-2024 core personal-loan vintages are forecast to UNDERPERFORM their ~11.3% blended target returns — the exact AI-underwriting credibility that the whole model rests on.